1-20 of 20
Robert S. Kerbel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy

Marta Paez-Ribes, Shan Man, Ping Xu, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5488–5498.
https://doi.org/10.1158/1078-0432.CCR-15-0915
Published: 14 December 2015
View articletitled, Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy
Open the PDF for Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy in another window
Includes: Supplementary data
Journal Articles

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis

Lucia B. Jilaveanu, Fabio Parisi, Meaghan L. Barr, Christopher R. Zito, William Cruz-Munoz, Robert S. Kerbel, David L. Rimm, Marcus W. Bosenberg, Ruth Halaban, Yuval Kluger, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (9): 2138–2147.
https://doi.org/10.1158/1078-0432.CCR-14-0861
Published: 30 April 2015
View articletitled, PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
Open the PDF for PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis in another window
Includes: Supplementary data
Journal Articles

Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer

Elizabeth Pham, Michael J. Birrer, Scott Eliasof, Edward G. Garmey, Douglas Lazarus, Christina R. Lee, Shan Man, Ursula A. Matulonis, Christian G. Peters, Ping Xu, Carolyn Krasner, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 808–818.
https://doi.org/10.1158/1078-0432.CCR-14-2810
Published: 16 February 2015
View articletitled, Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
Open the PDF for Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor

Sushil Kumar, Reza Bayat Mokhtari, Reihaneh Sheikh, Bing Wu, Libo Zhang, Ping Xu, Shan Man, Indhira Dias Oliveira, Herman Yeger, Robert S. Kerbel, Sylvain Baruchel
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5656–5667.
https://doi.org/10.1158/1078-0432.CCR-11-0078
Published: 01 September 2011
View articletitled, Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor
Open the PDF for Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor in another window
Journal Articles

Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts

Giulio Francia, Shan Man, Chyan-Jang Lee, Christina R. Lee, Ping Xu, Miriam E. Mossoba, Urban Emmenegger, Jeffrey A. Medin, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (20): 6358–6366.
https://doi.org/10.1158/1078-0432.CCR-09-0931
Published: 14 October 2009
View articletitled, Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts
Open the PDF for Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts in another window
Includes: Supplementary data
Journal Articles

Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy

John M. L. Ebos, Christina R. Lee, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5020–5025.
https://doi.org/10.1158/1078-0432.CCR-09-0095
Published: 12 August 2009
View articletitled, Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
Open the PDF for Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy in another window
Journal Articles

Effective Treatment of Advanced Human Melanoma Metastasis in Immunodeficient Mice Using Combination Metronomic Chemotherapy Regimens

William Cruz-Munoz, Shan Man, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (15): 4867–4874.
https://doi.org/10.1158/1078-0432.CCR-08-3275
Published: 29 July 2009
View articletitled, Effective Treatment of Advanced Human Melanoma Metastasis in Immunodeficient Mice Using Combination Metronomic Chemotherapy Regimens
Open the PDF for Effective Treatment of Advanced Human Melanoma Metastasis in Immunodeficient Mice Using Combination Metronomic Chemotherapy Regimens in another window
Journal Articles

Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent

Anthony J. Mutsaers, Giulio Francia, Shan Man, Christina R. Lee, John M.L. Ebos, Yan Wu, Larry Witte, Scott Berry, Malcolm Moore, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2397–2405.
https://doi.org/10.1158/1078-0432.CCR-08-1627
Published: 01 April 2009
View articletitled, Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent
Open the PDF for Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent in another window
Journal Articles

Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth

Fernando Doñate, Graham C. Parry, Yuval Shaked, Harvey Hensley, Xiaojun Guan, Ivy Beck, Ziva Tel-Tsur, Marian L. Plunkett, Mari Manuia, David E. Shaw, Robert S. Kerbel, Andrew P. Mazar
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (7): 2137–2144.
https://doi.org/10.1158/1078-0432.CCR-07-4530
Published: 01 April 2008
View articletitled, Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth
Open the PDF for Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth in another window
Journal Articles

High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma

Rena Buckstein, Robert S. Kerbel, Yuval Shaked, Rakesh Nayar, Cindy Foden, Ruth Turner, Christine R. Lee, Diane Taylor, Liying Zhang, Shan Man, Sylvain Baruchel, Diana Stempak, Francesco Bertolini, Michael Crump
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5190–5198.
https://doi.org/10.1158/1078-0432.CCR-06-0474
Published: 01 September 2006
View articletitled, High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma
Open the PDF for High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma in another window
Journal Articles

Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL–Based Paclitaxel

Sylvia S.W. Ng, Alex Sparreboom, Yuval Shaked, Christina Lee, Shan Man, Neil Desai, Patrick Soon-Shiong, William D. Figg, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4331–4338.
https://doi.org/10.1158/1078-0432.CCR-05-2762
Published: 20 July 2006
View articletitled, Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL–Based Paclitaxel
Open the PDF for Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL–Based Paclitaxel in another window
Journal Articles

Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts

Jeanne M. du Manoir, Giulio Francia, Shan Man, Miriam Mossoba, Jeffrey A. Medin, Alicia Viloria-Petit, Daniel J. Hicklin, Urban Emmenegger, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (3): 904–916.
https://doi.org/10.1158/1078-0432.CCR-05-1109
Published: 07 February 2006
View articletitled, Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts
Open the PDF for Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts in another window
Journal Articles

A Dynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose for Antiangiogenic Drugs

Urban Emmenegger, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7589–7592.
https://doi.org/10.1158/1078-0432.CCR-05-1387
Published: 08 November 2005
View articletitled, A Dynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose for Antiangiogenic Drugs
Open the PDF for A Dynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose for Antiangiogenic Drugs in another window
Journal Articles

Metronomic Low-Dose Chemotherapy Boosts CD95-Dependent Antiangiogenic Effect of the Thrombospondin Peptide ABT-510: A Complementation Antiangiogenic Strategy

Ronald Yap, Dorina Veliceasa, Urban Emmenegger, Robert S. Kerbel, Laura M. McKay, Jack Henkin, Olga V. Volpert
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6678–6685.
https://doi.org/10.1158/1078-0432.CCR-05-0621
Published: 15 September 2005
View articletitled, Metronomic Low-Dose Chemotherapy Boosts CD95-Dependent Antiangiogenic Effect of the Thrombospondin Peptide ABT-510: A Complementation Antiangiogenic Strategy
Open the PDF for Metronomic Low-Dose Chemotherapy Boosts CD95-Dependent Antiangiogenic Effect of the Thrombospondin Peptide ABT-510: A Complementation Antiangiogenic Strategy in another window
Journal Articles

Anti-Vascular Endothelial Growth Factor Receptor-2 Antibody Accelerates Renal Disease in the NZB/W F1 Murine Systemic Lupus Erythematosus Model

Hideaki Watanabe, Adam J. Mamelak, Elliot Weiss, Binghe Wang, Irwin Freed, Angela K. Brice, Lynn Wachtman, Kathleen L. Gabrielson, Naoko Yokota, Daniel J. Hicklin, Robert S. Kerbel, Mark Haas, Daniel N. Sauder
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (1): 407–409.
https://doi.org/10.1158/1078-0432.407.11.1
Published: 21 January 2005
View articletitled, Anti-Vascular Endothelial Growth Factor Receptor-2 Antibody Accelerates Renal Disease in the NZB/W F1 Murine Systemic Lupus Erythematosus Model
Open the PDF for Anti-Vascular Endothelial Growth Factor Receptor-2 Antibody Accelerates Renal Disease in the NZB/W F1 Murine Systemic Lupus Erythematosus Model in another window
Journal Articles

Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development

John W. Park, Robert S. Kerbel, Gary J. Kelloff, J. Carl Barrett, Bruce A. Chabner, David R. Parkinson, Jonathan Peck, Raymond W. Ruddon, Caroline C. Sigman, Dennis J. Slamon
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (11): 3885–3896.
https://doi.org/10.1158/1078-0432.CCR-03-0785
Published: 01 June 2004
View articletitled, Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Open the PDF for Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development in another window
Journal Articles

Reanalysis of Cancer Drugs: Old Drugs, New Tricks

George F. Vande Woude, Gary J. Kelloff, Raymond W. Ruddon, Han-Mo Koo, Caroline C. Sigman, J. Carl Barrett, Robert W. Day, Adam P. Dicker, Robert S. Kerbel, David R. Parkinson, William J. Slichenmyer
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (11): 3897–3907.
https://doi.org/10.1158/1078-0432.CCR-03-0786
Published: 01 June 2004
View articletitled, Reanalysis of Cancer Drugs: Old Drugs, New Tricks
Open the PDF for Reanalysis of Cancer Drugs: Old Drugs, New Tricks in another window
Journal Articles

Biomarkers, Surrogate End Points, and the Acceleration of Drug Development for Cancer Prevention and Treatment: An Update Prologue

Gary J. Kelloff, Robert C. Bast, Jr., Donald S. Coffey, Anthony V. D’Amico, Robert S. Kerbel, John W. Park, Raymond W. Ruddon, Gordon J. S. Rustin, Richard L. Schilsky, Caroline C. Sigman, George F. Vande Woude
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (11): 3881–3884.
https://doi.org/10.1158/1078-0432.CCR-03-0783
Published: 01 June 2004
View articletitled, Biomarkers, Surrogate End Points, and the Acceleration of Drug Development for Cancer Prevention and Treatment: An Update Prologue
Open the PDF for Biomarkers, Surrogate End Points, and the Acceleration of Drug Development for Cancer Prevention and Treatment: An Update Prologue in another window
Journal Articles

Differences in Therapeutic Indexes of Combination Metronomic Chemotherapy and an Anti-VEGFR-2 Antibody in Multidrug-resistant Human Breast Cancer Xenografts

Giannoula Klement, Ping Huang, Barbara Mayer, Shane K. Green, Shan Man, Peter Bohlen, Daniel Hicklin, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (1): 221–232.
Published: 01 January 2002
View articletitled, Differences in Therapeutic Indexes of Combination Metronomic Chemotherapy and an Anti-VEGFR-2 Antibody in Multidrug-resistant Human Breast Cancer Xenografts
Open the PDF for Differences in Therapeutic Indexes of Combination Metronomic Chemotherapy and an Anti-VEGFR-2 Antibody in Multidrug-resistant Human Breast Cancer Xenografts in another window
Journal Articles

Lack of Multicellular Drug Resistance Observed in Human Ovarian and Prostate Carcinoma Treated with the Proteasome Inhibitor PS-341

Andrea Frankel, Shan Man, Peter Elliott, Julian Adams, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (9): 3719–3728.
Published: 01 September 2000
View articletitled, Lack of Multicellular Drug Resistance Observed in Human Ovarian and Prostate Carcinoma Treated with the Proteasome Inhibitor PS-341
Open the PDF for Lack of Multicellular Drug Resistance Observed in Human Ovarian and Prostate Carcinoma Treated with the Proteasome Inhibitor PS-341 in another window